for all people living outside Germany you probably might not came across the HUS outbreak in the north of Germany, caused by multidrug resistant enterohaemorrhagic Escherichia coli (EHEC) strain O104:H4. The dramatic epidemy caused 29 deaths (as of June 10, 2011), which is an incredible number for an industrialized country like Germany. More than 2.800 new infected people were registered by the German Robert-Koch-Institute, 722 of these show serious symptoms for the haemolytic uremic syndrome (HUS), as of June 10, 2011.
This demonstrates once again the urgent need for novel and innovative therapeutic approaches to fight microbial pathogen attacks. Novel therapeutics like Patent US 7,939,492 and Patent US 7,850,975 are welcome.
Today we released some informations about the second-most popular ligand binding assay usually performed in the liquid phase (comes right behind the RT-qPCR, qPCR assays on top): the limulus amebocyte lysate (LAL) endotoxin detection assay, applied by the pharmaceutical industry and manufacturers to ensure endotoxin-free products.
On Monday we have a sort of Bank Holiday in Germany, so we´ll be back on Thursday next week. Have a nice weekend, your binding-assay.com team